TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25298352

Group type: EXPERIMENTAL
Intervention: Ginger (Zingiber officinale) capsules
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 92
Study: 23963375

Group type: EXPERIMENTAL
Intervention: With tenaculum
Number of subjects: 118

Group type: COMPARATOR
Intervention: Without tenaculum
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Tenaculum use
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Inadequate endometrial sampling
Number of subjects: 118
Study: 21450612

Group type: EXPERIMENTAL
Intervention: Contemporary cardiovascular risk prediction model
Number of subjects: 7168

Group type: EXPERIMENTAL
Intervention: External applicability of the model
Number of subjects: 7168

Group type: EXPERIMENTAL
Intervention: Significant predictors of cardiovascular events
Number of subjects: 7168

Group type: EXPERIMENTAL
Intervention: Major cardiovascular events recorded during follow-up
Number of subjects: 7168
Study: 19825326

Group type: EXPERIMENTAL
Intervention: Formulation A (15 mg of sibutramine)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Formulation B (15 mg of sibutramine)
Number of subjects: 62
Study: 17657689

Group type: EXPERIMENTAL
Intervention: Pegaptanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photodynamic treatment with Verteporfin
Number of subjects: 0
Study: 15040533

Group type: EXPERIMENTAL
Intervention: IFN-alpha2a + lamivudine (3TC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: IFN-alpha2b + lamivudine (3TC)
Number of subjects: 63
Study: 11438043

Group type: EXPERIMENTAL
Intervention: rhIL-11 15 microg/kg once-weekly
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 9683174

Group type: EXPERIMENTAL
Intervention: Supplementation with 3.5x the recommended dietary intake (RDI) of folate and vitamin B12 in wheat bran cereal for three months followed by ten times the RDI via tablets for a further three months
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Supplementation with 3.5x the recommended dietary intake (RDI) of folate and vitamin B12
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 106
Study: 7881228

Group type: EXPERIMENTAL
Intervention: Community-based homes (movers)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hospital (non-movers)
Number of subjects: 36
Study: 2452491

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) during hospital stay
Number of subjects: 23

Group type: COMPARATOR
Intervention: Spontaneous oral intake only during hospital stay
Number of subjects: 23
Study: 29361959

Group type: EXPERIMENTAL
Intervention: Supplemental parenteral nutrition (PN) strategy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care enteral nutrition (EN) delivery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 27612653

Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus reuteri
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 25644724

Group type: EXPERIMENTAL
Intervention: High-dose caffeine (loading 40 mg/kg/day and maintenance 20 mg/kg/day)
Number of subjects: 120
Study: 23659814

Group type: EXPERIMENTAL
Intervention: Family therapeutic conversation intervention (FAM-TC)
Number of subjects: 0
Study: 21128833

Group type: EXPERIMENTAL
Intervention: Anomia therapy involving cueing to improve retrieval of nouns, specific dosage and duration not mentioned.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anomia therapy (same as above)
Number of subjects: 13
Study: 18498792

Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap left intact distally (D group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intercostal muscle flap cut distally (C group)
Number of subjects: 160
Study: 16536959

Group type: EXPERIMENTAL
Intervention: Peer support group
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study: 12681025

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg t.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (t.i.d.)
Number of subjects: 0
Study: 11165725

Group type: EXPERIMENTAL
Intervention: Domiciliary monitoring (n=69)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: In-hospital monitoring (n=61)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Low-risk pregnant women (n=55)
Number of subjects: 130
Study: 9484423

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg and 400 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8159602

Group type: EXPERIMENTAL
Intervention: Picenadol 30 mg
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Codeine 90 mg
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 2831758

Group type: EXPERIMENTAL
Intervention: 25 mg captopril (group C; n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (group P; n = 12)
Number of subjects: 24
Study: 31305506

Group type: EXPERIMENTAL
Intervention: Ice packs
Number of subjects: 42

Group type: COMPARATOR
Intervention: Room-temperature pack
Number of subjects: 42
Study: 31486727

Group type: EXPERIMENTAL
Intervention: Home-Based Palliative Care (HBPC)
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Enhanced usual primary care
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Participant-reported outcome measures
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Caregiver outcome measures
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Participant survival time
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Participants' emergency department visits and hospitalizations
Number of subjects: 1155
Study: 29072245

Group type: EXPERIMENTAL
Intervention: Extended amoxicillin/clavulanic acid, 1 gram pre-operatively and then 625 mg BD for 5 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Prophylactic amoxicillin/clavulanic acid, 1 gram pre-operatively only
Number of subjects: 135

Group type: COMPARATOR
Intervention: Prophylactic levofloxacin, 1 gram pre-operatively only
Number of subjects: 135
Study: 25527998

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) as an adjunct to usual care
Number of subjects: 469

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 469
Study: 23935833

Group type: EXPERIMENTAL
Intervention: Placebo pills (described as Tylenol)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rest control
Number of subjects: 48
Study: 21937811

Group type: EXPERIMENTAL
Intervention: Sequential therapy with pantoprazole 40 mg injection, twice daily for 2 weeks, followed by pantoprazole 40 mg oral administration, twice daily for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg oral administration alone, twice daily for 4 weeks
Number of subjects: 80
Study: 19737592

Group type: EXPERIMENTAL
Intervention: E. amoenum aqueous extract (500 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16495393

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Trastuzumab (in HER2/neu-positive subgroup)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: No trastuzumab (in HER2/neu-positive subgroup)
Number of subjects: 1010
Study: 15246908

Group type: EXPERIMENTAL
Intervention: DASH diet with 50 mmol sodium/2,100 kcal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DASH diet with 100 mmol sodium/2,100 kcal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical American diet with 50 mmol sodium/2,100 kcal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical American diet with 100 mmol sodium/2,100 kcal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DASH diet with 150 mmol sodium/2,100 kcal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical American diet with 150 mmol sodium/2,100 kcal
Number of subjects: 0
Study: 11032271

Group type: EXPERIMENTAL
Intervention: 5 mg x kg(‐1) tramadol (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (Group 2)
Number of subjects: 60
Study: 9515971

Group type: EXPERIMENTAL
Intervention: Fluoxetine (mean dose 55 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8146588

Group type: EXPERIMENTAL
Intervention: Psychophysical thresholds measured using a modified method of limits.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological thresholds based on auditory steady-state potentials recorded from the scalp.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-frequency stimuli (480 Hz) for physiological thresholds.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-frequency stimuli (2000 Hz) for physiological thresholds.
Number of subjects: 0
Study: 30908085

Group type: EXPERIMENTAL
Intervention: Gaze-Contingent Music Reward Therapy (GC-MRT)
Number of subjects: 12
Study: 30052894

Group type: EXPERIMENTAL
Intervention: XANTUS
Number of subjects: 4020

Group type: COMPARATOR
Intervention: ROCKET AF
Number of subjects: 4020
Study: 27910117

Group type: EXPERIMENTAL
Intervention: Counselling in primary care
Number of subjects: 0
Study: 25362524

Group type: EXPERIMENTAL
Intervention: 150 mg fluconazole and a single vaginal globule of fenticonazole (600 mg)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: 150 mg fluconazole and a single vaginal globule of fenticonazole (600 mg) plus ten applications of a vaginal probiotic (Lactobacillus acidophilus, L. rhamnosus, Streptococcus thermophilus, L. delbrueckii subsp. bulgaricus) starting on the fifth day after azole treatment
Number of subjects: 436
Study: 23557551

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ramipril (5 mg/d)
Number of subjects: 40
Study: 21241965

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin and 25 mg rofecoxib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18703567

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Constant dual stimulation with GHRH/GHRP-2
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-arginine/GHRH (another instance)
Number of subjects: 22
Study: 15916222

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% cream and gel
Number of subjects: 31

Group type: COMPARATOR
Intervention: Tretinoin microsphere 0.04%
Number of subjects: 31

Group type: COMPARATOR
Intervention: Tretinoin microsphere 0.1%
Number of subjects: 31

Group type: COMPARATOR
Intervention: Negative control product
Number of subjects: 31
Study: 12542558

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg subcutaneously)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Sumatriptan (second intervention)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Acupuncture (second intervention)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 10391673

Group type: EXPERIMENTAL
Intervention: Oxybutynin XL (Ditropan XL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release oxybutynin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxybutynin XL
Number of subjects: 0
Study: 9034759

Group type: EXPERIMENTAL
Intervention: Pharmaton Capsules (multivitamins plus ginseng extract G115)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Multivitamin capsules (without ginseng)
Number of subjects: 625
Study: 2005078

Group type: EXPERIMENTAL
Intervention: Fluoxetine a.m. (20 to 80 mg daily for 5 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoxetine p.m. (20 to 80 mg daily for 5 weeks)
Number of subjects: 120
Study: 6848406

Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid (13 mg/kg . day)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (13 mg/kg . day)
Number of subjects: 5
Study: 31036108

Group type: EXPERIMENTAL
Intervention: TACE plus HIFU
Number of subjects: 90

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 90
Study: 30395547

Group type: EXPERIMENTAL
Intervention: Chronic mild depressive symptoms (Class 2, 47% of the sample)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Persistent moderate/severe depressive symptoms (Class 3, 15% of the sample)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Minimal or no depressive symptoms (Class 1, 38% of the sample)
Number of subjects: 1172
Study: 27442803

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 1459

Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (iv. PCA)
Number of subjects: 1459
Study: 24503689

Group type: EXPERIMENTAL
Intervention: Open-door laminoplasty
Number of subjects: 92

Group type: COMPARATOR
Intervention: French-door laminoplasty
Number of subjects: 92
Study: 22410815

Group type: EXPERIMENTAL
Intervention: Diet soda (240 mL cola-flavored caffeine-free)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Carbonated water
Number of subjects: 44
Study: 20112525

Group type: EXPERIMENTAL
Intervention: Therapeutic pressure (15 msw, 253 kPa)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (2 msw, 120 kPa)
Number of subjects: 22
Study: 17573591

Group type: EXPERIMENTAL
Intervention: Self-reported STD in the last 6 months
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Condom use with male clients
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Unprotected sex with boyfriends
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Unprotected sex with one-night-stand partners
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Factors associated with condom use
Number of subjects: 293
Study: 15370397

Group type: EXPERIMENTAL
Intervention: Topical 2% azithromycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical 2% erythromycin
Number of subjects: 40
Study: 11241254

Group type: EXPERIMENTAL
Intervention: Strontium only (strontium 4 Mci in Week 1 and Week 12)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vinblastine 4 mg/m(2) per week for 3 weeks then 1 week off and estramustine, 10 mg/kg per day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination of CHEMO and STRONT
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 29
Study: 10997166

Group type: EXPERIMENTAL
Intervention: 250 i.u. of intrathecal human anti-tetanus immunoglobulin (TIG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham procedure mimicking lumbar puncture
Number of subjects: 36
Study: 7798415

Group type: EXPERIMENTAL
Intervention: 400 micrograms OTFC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 micrograms OTFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2722310

Group type: EXPERIMENTAL
Intervention: Metoclopramide, 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BRL 24924, 2 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31099217

Group type: EXPERIMENTAL
Intervention: Electroacupuncture group A (dilatational wave, 2 Hz/100 Hz)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture group B (continuous wave, 2 Hz)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture group C (continuous wave, 100 Hz)
Number of subjects: 120
Study: 28638029

Group type: EXPERIMENTAL
Intervention: Pantogam (hopantenic acid) administered in tablets (250 mg) at a therapeutic dose of 30 mg/kg of body mass, divided into 2 doses, during 4 months.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pantogam (hopantenic acid)
Number of subjects: 100
Study: 25525862

Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIE)
Number of subjects: 10
Study: 23472599

Group type: EXPERIMENTAL
Intervention: Oral hormone therapy (n = 26)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (n = 20)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 76
Study: 21809025

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FOLFOX regimen (oxaliplatin 100 mg/m² on day 1, leucovorin 200 mg/m² on day 1, 5-fluorouracil 2000 mg/m² as a 48-h continuous infusion for up to six courses in the 1st year after transplantation)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 95
Study: 19783561

Group type: EXPERIMENTAL
Intervention: Praneem polyherbal vaginal tablets
Number of subjects: 99

Group type: COMPARATOR
Intervention: Betadine vaginal pessary
Number of subjects: 99
Study: 16779513

Group type: EXPERIMENTAL
Intervention: Aprotinin (2,000,000 KIU starting dose, followed by 500,000 KIU per hour)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 14569109

Group type: EXPERIMENTAL
Intervention: Alfacalcidol 0.5 micro g by mouth daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study: 11016328

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 161

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 161
Study: 8792262

Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention with normally developing peers, matched by sex and age, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 1293915

Group type: EXPERIMENTAL
Intervention: Combined multidrug treatment (MDT) and immunotherapy with heat killed Mycobacterium w or BCG, administered intradermally every six months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multidrug treatment (MDT) alone
Number of subjects: 0
Study: 3838188

Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy plus extensive radiotherapy (mantle and paraaortic areas)
Number of subjects: 335

Group type: COMPARATOR
Intervention: MOPP chemotherapy plus involved field radiotherapy
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy plus extensive radiotherapy
Number of subjects: 335
Study: 30973337

Group type: EXPERIMENTAL
Intervention: SFSW intervention (Web-based training program with 11 weekly themes and associated telephone sessions)
Number of subjects: 1114
Study: 30384087

Group type: EXPERIMENTAL
Intervention: Personal-narrative intervention
Number of subjects: 1449

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1449
Study: 28376080

Group type: EXPERIMENTAL
Intervention: CAP-CRT
Number of subjects: 114

Group type: COMPARATOR
Intervention: GEM-CRT
Number of subjects: 114
Study: 25220844

Group type: EXPERIMENTAL
Intervention: Tyrosine (300 mg/kg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 23609132

Group type: EXPERIMENTAL
Intervention: Marijuana (1.98% THC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Marijuana (3.56% THC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dronabinol (20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Marijuana (1.98%, 3.56%)
Number of subjects: 30
Study: 21890886

Group type: EXPERIMENTAL
Intervention: 6% w/v hydroxyethyl starch solution (HES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hartmann (crystalloid) solution (HS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion
Number of subjects: 60
Study: 19695776

Group type: EXPERIMENTAL
Intervention: Internet treatment group (8 weeks of online modules including relaxation training, cognitive strategies, parent operant techniques, communication strategies, and sleep and activity interventions)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Internet treatment group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control group (current medical care only)
Number of subjects: 48
Study: 17908057

Group type: EXPERIMENTAL
Intervention: Periosteal stimulation therapy (PST)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control PST
Number of subjects: 88
Study: 15472602

Group type: EXPERIMENTAL
Intervention: Inflow from the common femoral artery (CFA)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Inflow from below the common femoral artery
Number of subjects: 160
Study: 12426738

Group type: EXPERIMENTAL
Intervention: Low-dose spiral CT screening
Number of subjects: 0
Study: 9680783

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 26
Study: 9231947

Group type: EXPERIMENTAL
Intervention: Org 10172 (1250 anti‐Xa Units s.c. once daily)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Heparin sodium (5000 IU s.c. twice daily)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179
Study: 2493376

Group type: EXPERIMENTAL
Intervention: Antibiotics plus intravenous gammaglobulin (i.v. IgG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Antibiotics (cefataxim and amikacin)
Number of subjects: 33
Study: 29371246

Group type: EXPERIMENTAL
Intervention: 0.8 mg daily folic acid + 10 mg enalapril
Number of subjects: 16413

Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 16413
Study: 29132440

Group type: EXPERIMENTAL
Intervention: Immediate, intensive periodontal treatment (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed treatment (n=30)
Number of subjects: 60
Study: 26016052

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy and CPAP (Group B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pharmacological therapy only (Group A)
Number of subjects: 36